Exploring the Power of Innovative Ingredients in Cardiology:
Cardiovascular disease is responsible for a significant number of deaths. It affects the heart and blood vessels. The field of cardiology has introduced several new medications to treat various heart conditions. Healthcare providers may prescribe medications or recommend lifestyle changes to manage cardiovascular disease. Detecting the disease can make it easier to treat.
Cardiovascular disease is a group of conditions that can affect one or multiple parts of the heart and blood vessels. A person may experience symptoms or not feel anything at all. The cardiology pipeline is not lacking in new ideas, even if there is a shortage of new products. New products will improve the scope of cardiac function and metabolism.
 |
| A young girl with severe pain |
- Inclisiran: The US FDA has approved Inclisiran, a new type of cholesterol-lowering medication. It is an RNA interference therapy that targets a specific gene involved in cholesterol production. Clinical trials have shown it can reduce LDL cholesterol by up to 50%. Inclisiran is a medication used for the treatment of high cholesterol. It is a small interfering RNA (siRNA) therapy that targets PCSK9, a protein that controls cholesterol levels in the blood. By inhibiting PCSK9, Inclisiran helps reduce low-density lipoprotein (LDL) cholesterol, also known as "bad" cholesterol, in the blood. It is given as a subcutaneous injection every six months with promising results in clinical trials for reducing LDL cholesterol levels with fewer side effects than other cholesterol-lowering medications.
- Vericiguat: Cardiologists prescribe Vericiguat for heart failure with reduced ejection fraction. It stimulates an enzyme called soluble guanylate cyclase, which helps relax blood vessels and improve blood flow. Vericiguat is a medication used for the treatment of heart failure. It is a soluble guanylate cyclase stimulator that increases cyclic guanosine monophosphate (cGMP) for blood vessel relaxation and fluid balance. By increasing cGMP levels, Vericiguat helps reduce the workload on the heart and improve the symptoms of heart failure. It is taken orally once a day and has shown promising results in clinical trials for reducing the risk of hospitalisation and improving survival rates.
- Omecamtiv Mecarbil: Omecamtiv Mecarbil is a medication used for heart failure. It is a cardiac myosin activator that increases the efficiency of cardiac muscle contraction, thereby improving the heart's ability to pump blood. It is currently undergoing clinical trials and shows promising results for improving heart function and reducing the risk of hospitalisation.
- Edoxaban: Edoxaban is an anticoagulant medication for averting stroke and systemic embolism in patients with non-valvular atrial fibrillation and venous thromboembolism. It works by inhibiting the activity of Factor Xa, a protein involved in blood clotting. Edoxaban has a lower risk of bleeding than other anticoagulants dosage is once daily.
These new medications and other recent developments in cardiology are improving outcomes and quality of life. Here are five more new molecules in cardiology that can help improve the health and safety of the heart.
- Rivaroxaban: Doctors use rivaroxaban as an anticoagulant medication for blood clots in patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It works by inhibiting the activity of Factor Xa, a protein involved in blood clotting. Rivaroxaban has a lower risk of bleeding than other anticoagulants. Doctors recommend taking it orally once or twice daily. Regular monitoring of kidney function is crucial when taking rivaroxaban due to its potential elimination through the kidneys and the increased risk of bleeding with impaired kidney function. Therefore, healthcare providers may need to adjust the dosage of rivaroxaban based on the patient's kidney function and monitor kidney function regularly during treatment.
- Evolocumab is a monoclonal antibody that lowers LDL cholesterol levels. It targets PCSK9, a protein that regulates LDL cholesterol levels.
- Ivabradine: Ivabradine is an FDA-approved medication in the USA for stable angina and heart failure with reduced ejection fraction. It reduces the heart rate and improves the heart's efficiency, thereby reducing symptoms and improving overall heart function. Ivabradine is a medication used for the treatment of heart failure and angina. It works by inhibiting the activity of the current in the sinoatrial node, which slows down the heart rate without affecting blood pressure. Ivabradine can help to improve the heart's efficiency and reduce the workload on the heart by lowering the heart rate. It is taken orally twice daily and has shown promising results in clinical trials for reducing the risk of hospitalisation and improving the symptoms of heart failure and angina.
- Alirocumab: Another monoclonal antibody that lowers LDL cholesterol levels. It works by targeting PCSK9, similar to evolocumab.
Entresto (sacubitril and valsartan, 24 mg and 26 mg film-coated tablets):
Entresto is a combination medication that contains two active ingredients, sacubitril and valsartan. Entresto is a brand of Novartis. Doctors use this combination of heart failure with a reduced ejection fraction. It inhibits the renin-angiotensin-aldosterone (RAA) system and enhances natriuretic peptides.
- Entresto is a medication used for congestive heart failure with reduced ejection fraction, where the heart cannot drain enough blood to meet the body's needs.
- Sacubitril is an inhibitor of neprilysin, an enzyme that breaks down several peptides that promote vasodilation, natriuresis, and diuresis.
- Inhibition of neprilysin by sacubitril increases the levels of these peptides, reducing the workload on the heart and improving cardiac function.
- Valsartan is an angiotensin II receptor blocker (ARB) that blocks the vasoconstrictive effects of angiotensin II, a hormone that causes blood vessels to constrict and increase blood pressure.
- Valsartan helps lower blood pressure and reduce the workload on the heart by blocking the effects of angiotensin II.
- Sacubitril and valsartan work together to improve heart failure symptoms, reduce the risk of hospitalisation, and improve survival rates.
Entresto (sacubitril and valsartan) is more effective than traditional treatments for heart failure, such as ACE inhibitors or ARBs, and has become a recommended treatment option for patients with heart failure and reduced ejection fraction. However, it is vital to note that Entresto may not be suitable for all patients' needs under the guidance of a cardiologist.
Some potential side effects of Entresto include low blood pressure, kidney problems, high potassium levels, and angioedema (swelling under the skin). Your cardiologist can discuss the benefits and risks of Entresto with you and determine if it is an appropriate treatment option for your condition.
As we continue to learn more about cardiovascular disease and the factors to its development, it's clear that innovative treatments and ingredients are essential in the fight against this devastating condition. Some advancements offer exciting possibilities for improving heart health and preventing cardiovascular disease. Staying informed about the latest research and developments in cardiovascular disease treatment can help healthcare professionals and patients take steps towards a healthier future.